Investment
Features
FeesSafety
Academy
More
Pluang+

Crude oil hits six-week high amid US-Iran tensions, but US gas prices may drop this fall.

Market News
07 Sep 2026
New York Post
View Source
Bearish
Crude oil hits six-week high amid US-Iran tensions, but US gas prices may drop this fall.

Crude oil prices surged to their highest in six weeks due to renewed US-Iran conflicts and attacks on Saudi Aramco facilities, raising concerns over Middle East energy supplies. Brent crude reached $97.73 per barrel, and US West Texas Intermediate hit $93.10. Despite this, an oil expert predicts US gasoline prices could fall in October as refiners switch to cheaper winter blends. However, diesel prices may rise sharply, especially in the Northeast, due to low inventories and increased demand for heating and agriculture. The situation remains fragile, with potential supply shocks looming amid geopolitical tensions and refinery damages in the Middle East and Russia.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
34 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
S&P 500 shows dot-com bubble-like risks with high valuation and narrow rally in tech and energy sectors.

S&P 500 shows dot-com bubble-like risks with high valuation and narrow rally in tech and energy sectors.

The S&P 500 currently exhibits a high CAPE valuation of 41x and a market concentration reminiscent of the dot-com bubble peak, with the rally primarily driven by tech and energy sectors. This narrow market breadth raises systemic risk concerns simila...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App